Related Experiment Video
Updated: Jun 27, 2026
08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
PEDF as an emerging therapeutic candidate for osteosarcoma.
Crispin R Dass1, Eugene T H Ek, Peter F M Choong
1Department of Orthopaedics and Surgery, University of Melbourne, St Vincent's Hospital, Melbourne, Australia. crispin.dass@svhm.org.au
Current Cancer Drug Targets
|December 17, 2008
Summary
Pigment epithelium-derived factor (PEDF) shows promise as a novel biological therapy for osteosarcoma (OS), a bone cancer affecting adolescents. Research indicates PEDF inhibits tumor growth and may reduce relapse rates, offering a less toxic treatment option.
Area of Science:
- Oncology
- Molecular Biology
- Biomedical Engineering
Background:
- Osteosarcoma (OS) is a prevalent bone cancer in adolescents with a significant relapse rate despite current treatments.
- Elucidating the molecular basis of OS is crucial for developing targeted biological therapies with reduced toxicity.
- Pigment epithelium-derived factor (PEDF) has emerged as a potential therapeutic agent for OS.
Purpose of the Study:
- To investigate the role of pigment epithelium-derived factor (PEDF) in controlling osteosarcoma (OS) progression.
- To explore PEDF's therapeutic potential as a biological agent against OS.
- To advance PEDF as a drug candidate towards clinical trials for OS treatment.
Main Methods:
- Utilizing orthotopic, spontaneously metastasizing models of osteosarcoma in preclinical studies.
- Administering PEDF as recombinant protein, via overexpression, or as short peptide derivatives.
- Analyzing the inverse relationship between PEDF and vascular endothelial growth factor (VEGF) expression in bone growth plate cartilage.
Main Results:
- PEDF demonstrates tumor inhibition in preclinical OS models.
- PEDF expression is inversely correlated with vascular endothelial growth factor (VEGF) expression in growing bone.
- PEDF exhibits multiple anti-tumor mechanisms beyond its known anti-angiogenic activity.
Conclusions:
- Pigment epithelium-derived factor (PEDF) is a promising biological therapeutic candidate for osteosarcoma.
- PEDF's multifaceted anti-cancer properties warrant further investigation for OS treatment.
- Development of drug delivery systems, like nanoparticles, is key to advancing PEDF towards clinical application for OS.
